Breast Cancer Clinical Trial
Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor
Summary
A retrospective study of de-identified (to preserve patient privacy) patient information from the Flatiron Health Analytic Database to compare effectiveness (i.e., overall survival) of first line palbociclib + aromatase inhibitor (AI) versus AI alone treatment in postmenopausal women or men with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (MBC) in the United States clinical practices
Eligibility Criteria
Inclusion Criteria:
Confirmed HR+/HER2- status after MBC diagnosis.
Received palbociclib + AI or AI as first-line therapy
Exclusion Criteria:
Evidence of prior treatment with other CDK4/6I, AI, tamoxifen, raloxifene, toremifene, or Fulvestrant for MBC
First structured activity greater than 90 days after MBC diagnostic date
Treatment with a CDK4/6 inhibitor as part of a clinical trial
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
New York New York, 10017, United States
How clear is this clinincal trial information?
